7 June 2021 - Submission based on Phase 2/3 study of mRNA-1273 in adolescents ages 12 to less than 18 in the U.S.

Moderna today announced that it has submitted for authorisation of its COVID-19 vaccine in adolescents with Health Canada.

Read Moderna press release